A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Dexamethasone (Primary) ; Prednisolone
- Indications Ocular inflammation
- Focus Therapeutic Use
- Sponsors EyePoint Pharmaceuticals; Icon Bioscience
- 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. acquired Icon Bioscience and subsequently changed its name to EyePoint Pharmaceuticals.
- 15 Aug 2017 Status changed from recruiting to completed.
- 14 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.